Berardinelli Diletta, Kutzler Johannes, Taoussi Omayema, Zaami Simona, Pichini Simona, Basile Giuseppe, Busardò Francesco Paolo, Auwärter Volker, Carlier Jeremy
Marche Polytechnic University, Department of Biomedical Sciences and Public Health, Section of Legal Medicine, Unit of Forensic Toxicology, Ancona, Italy.
Institute of Forensic Medicine, Forensic Toxicology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Arch Toxicol. 2025 Apr 29. doi: 10.1007/s00204-025-04023-1.
The emergence of novel synthetic opioids (NSOs) poses significant challenges to public health, toxicologists, and law enforcement. Since the comprehensive scheduling of fentanyl analogues in many countries worldwide, several non-fentanyl NSOs have emerged on the illicit drug market, increasing the risks of addiction and fatal overdoses. Dipyanone, a methadone-like NSO, was first identified in drug seizures in 2021 and later also in postmortem cases. This study aimed to assess the metabolism of dipyanone in humans using in silico predictions, in vitro human hepatocyte incubations, and authentic urine specimens. Dipyanone was primarily metabolised through the opening of the pyrrolidine ring to form the corresponding N-butan-4-ol or N-butanoic acid compound, followed by cyclisation to 4'-[2-ethylidene-5-methyl-3,3-diphenylpyrrolidin-1-yl]butan-1'-ol (EMDPB) and 4'-[2-ethylidene-5-methyl-3,3-diphenylpyrrolidin-1-yl]butanoic acid (EMDPBA); other metabolic transformations included hydroxylation, reduction, and O-glucuronidation. We propose EMDPB and EMDPBA as specific biomarkers of dipyanone consumption. Additionally, dipyanone's activation of µ- (MOR), κ- (KOR), and δ- (DOR) opioid receptors was evaluated with a homogeneous time-resolved fluorescence-based GTP G binding assay. The half-maximal effective concentration (EC) and maximum effect (E) were 96.8 nM and 106% (compared to fentanyl at MOR), 380.4 nM and 13% (compared to U-50488 at KOR), and 1067 nM and 56% (compared to SNC-80 at DOR). Dipyanone's opioid receptor activation pattern was similar to that of methadone, with a strong agonistic effect at MOR, potentially inducing potent analgesic effects with health risks through the central nervous system and respiratory depression, as well as an abuse and dependence potential. Further pharmacokinetic and pharmacodynamic studies should be conducted to better understand the toxicological relevance of dipyanone.
新型合成阿片类药物(NSOs)的出现给公共卫生、毒理学家和执法部门带来了重大挑战。自全球许多国家对芬太尼类似物进行全面管制以来,几种非芬太尼类NSOs出现在非法药物市场上,增加了成瘾和致命过量用药的风险。二吡酮是一种类似美沙酮的NSO,于2021年在缉获毒品中首次被发现,后来在尸检病例中也有发现。本研究旨在通过计算机预测、体外人肝细胞孵育和真实尿液标本评估二吡酮在人体内的代谢情况。二吡酮主要通过吡咯烷环的开环代谢形成相应的N-丁-4-醇或N-丁酸化合物,随后环化生成4'-[2-亚乙基-5-甲基-3,3-二苯基吡咯烷-1-基]丁-1'-醇(EMDPB)和4'-[2-亚乙基-5-甲基-3,3-二苯基吡咯烷-1-基]丁酸(EMDPBA);其他代谢转化包括羟基化、还原和O-葡萄糖醛酸化。我们提议将EMDPB和EMDPBA作为二吡酮使用的特异性生物标志物。此外,使用基于均相时间分辨荧光的GTP G结合试验评估了二吡酮对μ-(MOR)、κ-(KOR)和δ-(DOR)阿片受体的激活作用。半数最大有效浓度(EC)和最大效应(E)分别为96.8 nM和106%(与MOR上的芬太尼相比)、380.4 nM和13%(与KOR上的U-50488相比)以及1067 nM和56%(与DOR上的SNC-80相比)。二吡酮的阿片受体激活模式与美沙酮相似,在MOR上具有强烈的激动作用,可能通过中枢神经系统和呼吸抑制诱导强效镇痛作用以及滥用和依赖潜力。应进行进一步的药代动力学和药效学研究以更好地了解二吡酮的毒理学相关性。